SUPPLEMENTAL TABLES

Supplemental table 1. Baseline characteristics by eGFR and albuminuria subgroup.

Abbreviations: BMI body mass index, eGFR estimated glomerular filtration rate (calculated using the Chronic Kidney Disease Epidemiology Collaboration equation), uACR urinary albumin-creatinine ratio, ACE angiotensin-converting enzyme, ARB angiotensin-II receptor blocker.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | eGFR ≥60mL/min/1.73m2, uACR <3mg/mmol (n=115794) | eGFR ≥60mL/min/1.73m2, uACR 3-30mg/mmol (n=29326) | eGFR ≥60mL/min/1.73m2, uACR ≥30mg/mmol (n=3120) | eGFR <60mL/min/1.73m2, any level of albuminuria (n=9153) |
| *Sociodemographic characteristics* |  |  |  |  |
| Age (years) | 58 ±11 | 58 ±11 | 56 ±11 | 70 ±7 |
| Male sex | 67564 (58%) | 17820 (61%) | 2035 (65%) | 4302 (47%) |
| Ethnicity |  |  |  |  |
| White | 86620 (75%) | 20547 (70%) | 1996 (64%) | 7317 (80%) |
| South Asian | 16104 (14%) | 5261 (18%) | 681 (22%) | 806 (9%) |
| Black | 7137 (6%) | 1869 (6%) | 233 (8%) | 716 (8%) |
| Other | 1894 (2%) | 671 (2%) | 92 (3%) | 119 (1%) |
| Mixed | 1279 (1%) | 354 (1%) | 61 (2%) | 73 (1%) |
| Not stated/Unknown | 2760 (2%) | 624 (2%) | 57 (2%) | 122 (1%) |
| Index of multiple deprivation deciles |  |  |  |  |
| 1-2 | 20083 (17%) | 4422 (15%) | 406 (13%) | 1597 (17%) |
| 3-4 | 21032 (18%) | 4927 (17%) | 447 (14%) | 1741 (19%) |
| 5-6 | 22141 (19%) | 5585 (19%) | 548 (18%) | 1834 (20%) |
| 7-8 | 25775 (22%) | 6861 (23%) | 778 (25%) | 1990 (22%) |
| 9-10 | 26763 (23%) | 7531 (26%) | 940 (30%) | 1991 (22%) |
| *Laboratory and vital signs measurements* |  |  |  |  |
| BMI (kg/m2) | 32 ±7 | 33 ±7 | 33 ±7 | 32 ±6 |
| Systolic blood pressure (mmHg) | 132 ±13 | 134 ±14 | 137 ±16 | 134 ±15 |
| Diastolic blood pressure (mmHg) | 78 ±9 | 79 ±9 | 80 ±10 | 75 ±9 |
| Total cholesterol (mmol/L) | 4.4 ±1.1 | 4.5 ±1.2 | 4.7 ±1.4 | 4.3 ±1.1 |
| HbA1c (mmol/mol) | 74 ±18 | 79 ±19 | 82 ±20 | 70 ±19 |
| eGFR (mL/min/1.73m2) | 95 ±14 | 96 ±15 | 95 ±17 | 48 ±9 |
| uACR (mg/mmol) | 0.9 [0.6, 1.5] | 5.7 [3.8, 10.0] | 49.7 [37.4, 70.4] | 2.0 [0.8, 6.3] |
| *Comorbidities* |  |  |  |  |
| Diabetes duration at treatment start (years) | 6.9 [3.6, 11.1] | 7.3 [3.8, 11.8] | 8.0 [4.0, 13.1] | 10.4 [6.1, 15.0] |
| Smoking status |  |  |  |  |
| Non-smoker | 62134 (54%) | 14778 (50%) | 1463 (47%) | 4858 (53%) |
| Ex-smoker | 36338 (31%) | 9008 (31%) | 926 (30%) | 3432 (38%) |
| Current smoker | 17323 (15%) | 5540 (19%) | 731 (23%) | 863 (9%) |
| Hypertension | 58225 (50%) | 17067 (58%) | 2043 (66%) | 7331 (80%) |
| Atrial fibrillation | 2662 (2%) | 836 (3%) | 117 (4%) | 608 (7%) |
| Previous diabetic keto-acidosis | 466 (0%) | 174 (1%) | 29 (1%) | 47 (1%) |
| Previous mycotic genital infection | 13142 (11%) | 3392 (12%) | 358 (12%) | 769 (8%) |
| Hospitalisation in previous year | 21594 (19%) | 6067 (21%) | 759 (24%) | 2725 (30%) |
| *Medications* |  |  |  |  |
| Calendar year at baseline |  |  |  |  |
| 2013 | 13953 (12%) | 3231 (11%) | 333 (11%) | 1346 (15%) |
| 2014 | 14896 (13%) | 3627 (12%) | 387 (12%) | 1277 (14%) |
| 2015 | 16781 (15%) | 4144 (14%) | 432 (14%) | 1404 (15%) |
| 2016 | 15027 (13%) | 3775 (13%) | 389 (13%) | 1293 (14%) |
| 2017 | 15110 (13%) | 3897 (13%) | 378 (12%) | 1140 (13%) |
| 2018 | 15659 (14%) | 4077 (14%) | 446 (14%) | 1161 (13%) |
| 2019 | 15729 (14%) | 4208 (14%) | 489 (16%) | 1053 (11%) |
| 2020 | 9639 (8%) | 2367 (8%) | 266 (9%) | 479 (5%) |
| Number of current antihyperglycaemic treatments |  |  |  |  |
| 1 | 11934 (10%) | 2587 (9%) | 239 (8%) | 2287 (25%) |
| 2 | 66650 (58%) | 15825 (54%) | 1566 (50%) | 4375 (48%) |
| 3+ | 37210 (32%) | 10914 (37%) | 1315 (42%) | 2491 (27%) |
| On metformin | 98998 (86%) | 25561 (87%) | 2727 (87%) | 5597 (61%) |
| On insulin | 5872 (5%) | 2225 (8%) | 339 (11%) | 839 (9%) |
| On ACE-inhibitor or ARB | 64227 (56%) | 21284 (73%) | 2664 (85%) | 8006 (88%) |
| Treatment arm |  |  |  |  |
| SGLT2-inhibitor | 42338 (37%) | 11571 (40%) | 1291 (41%) | 776 (9%) |
| DPP4-inhibitor/sulfonylurea | 73456 (63%) | 17755 (60%) | 1829 (59%) | 8377 (91%) |

Supplemental Table 2. Performance measures of the raw and recalibrated Chronic Kidney Disease Prognosis Consortium (CKD-PC) risk score for kidney disease progression.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | C statistic | Brier score | Baseline hazard | Calibration slope |
| eGFR ≥60mL/min/1.73m2 |  |  |  |  |
| Raw risk score | 0.653 (0.648; 0.659) | 0.01164 (0.01093; 0.01235) | - | - |
| Baseline hazard update | 0.01164 (0.01093; 0.01236) | 0.9881 (0.9878; 0.9884) | - |
| Overall calibration slope | 0.01169 (0.01097; 0.01241) | 0.9897 (0.9890; 0.9904) | 1.6689 (1.4958; 1.8420)\* |

95% confidence intervals given between brackets.   
\*Corrected for optimism (-0.0026) using bootstrap internal validation.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | Kidney disease progression (≥50% decline in eGFR) | ≥40% decline in eGFR | Progression to severely increased albuminuria | Diabetic ketoacidosis | Mycotic genital infection |
| * eGFR ≥60mL/min/1.73m2, uACR <3mg/mmol | 0.35% (0.21; 0.58%) | 0.58% (0.35%; 0.94%) | 0.24% (0.18; 0.33%) | -0.17% (-0.10; -0.30%) | -4.49% (-2.78; -9.47%) |
| * eGFR ≥60mL/min/1.73m2, uACR 3-30mg/mmol (CKD-PC risk score <80th percentile) | 0.38% (0.23; 0.62%) | 0.61% (0.38%; 0.97%) | 0.58% (0.38; 1.12%) | -0.17% (-0.10; -0.30%) | -4.26% (-2.76; -9.04%) |
| * eGFR ≥60mL/min/1.73m2, uACR 3-30mg/mmol (CKD-PC risk score ≥80th percentile) | 0.85% (0.55; 1.28%) | 1.39% (0.94%; 2.04%) | 0.83% (0.53; 1.70%) | -0.38% (-0.20; -0.80%) | -4.77% (-2.52; -9.01%) |
| * eGFR <60mL/min/1.73m2 | 1.94% (1.34; 3.10%) | 2.62% (1.84%; 3.96%) | 0.59% (0.43; 0.96%) | -0.20% (-0.12; -0.37%) | -3.71% (-1.76; -6.48%) |
| * uACR ≥30mg/mmol | 1.21% (0.67; 2.17%) | 1.89% (1.06%; 3.25%) | - | -0.26% (-0.14; -0.51%) | -3.84% (-2.49; -8.10%) |

Supplemental Table 3. Median observed absolute risk reduction with SGLT2-inhibitors for kidney disease progression (≥50% decline in eGFR, ESKD, or death due to kidney-related causes), ≥40% decline in eGFR (or ESKD or death due to kidney-related causes), progression to severely increased albuminuria, diabetic ketoacidosis, and mycotic genital infection by eGFR and albuminuria subgroup.

\*Multivariable-adjusted absolute risk reductions in percentages. Median values shown with interquartile range in brackets.   
Absolute risk reductions for outcome amputation were not calculated as SGLT2-inhibitors did not significantly increase this risk.  
Abbreviations: eGFR estimated glomerular filtration rate; uACR urinary albumin/creatinine ratio; CKD-PC Chronic Kidney Disease Prognosis Consortium; CI confidence interval.